Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas
Open Access
- 1 April 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (4) , 535-541
Abstract
First-line systemic treatment for metastatic soft-tissue sarcomas (STSs) has hardly improved over 40 years, doxorubicin being the standard approach; no significant overall survival (OS) benefit has been demonstrated with combination schemes.1-5 Nevertheless, anthracycline-based polychemotherapy regimens can be recommended if the aim is surgical resection or fast palliation, since they offer a significantly higher probability of tumor shrinkage.6Keywords
This publication has 34 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade SarcomaSarcoma, 2013
- A retrospective study of SBRT of metastases in patients with primary sarcomaMedical Oncology, 2012
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind studyEuropean Journal of Cancer, 2012
- Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of actionEuropean Journal of Pharmacology, 2011
- In vitro radiosensitisation by trabectedin in human cancer cell linesEuropean Journal of Cancer, 2008
- Dynamics of cell cycle phase perturbations by trabectedin (ET‐743) in nucleotide excision repair (NER)‐deficient and NER‐proficient cells, unravelled by a novel mathematical simulation approachCell Proliferation, 2007
- Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T LymphocytesCancer Research, 2004
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989